The diagnostic procedures in patients with suspected fatty liver disease-with or without known alcohol consumption-should be standardized and generally accepted. We therefore present a guideline, summarizing the current concepts of etiology, diagnostic as well as differential diagnostic of patients with fatty liver disease. Alcoholic as well as and non-alcoholic fatty liver are characterised by lipid deposition in hepatocytes. The diagnosis of steatosis is made when lipid deposition exceeds 5% of hepatocytes, while involvement of more than 50% is called "fatty liver". An additional inflammatory reaction leads to alcoholic (ASH) or non-alcoholic steatohepatitis (NASH). Steatohepatitis is present when both inflammatory infiltrates of mixed cells in the small liver lobules as well as liver cell injury in terms of ballooning can be detected. Liver biopsy represents the "golden standard" for confirming diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease. The differential diagnosis of ASH vs. NASH cannot be made on the basis of histological criteria alone. Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a "Brunt Score" or "NAS" (NAFLD activity score), providing the basis on which to decide whether or not steatohepatitis is present. People at increased risk of developing a fatty liver possess an increased risk of developing chemotherapy-associated steatohepatitis. Histologically, pediatric NASH differs from adult NASH and is often only clinically manifest through a mild if persistent elevation in transaminases.
Introduction
It has long been known that the typical manifestations of alcoholic liver damage (including cirrhosis of the liver) can also be found in patients who consume no alcohol. For such persons, the incorrect diagnosis of "alcohol-related liver disease" on the basis of the histopathological findings can have grave social, legal, and insurance implications.
The term "non-alcoholic steatohepatitis" (NASH) was coined by Ludwig et al. [1] in 1980; the definition of the entity was later expanded [2] . Patients who manifested the typical histomorphological picture of alcoholic steatohepatitis (ASH), but without immoderate alcohol consumption, were described [3] .
Diagnosis by means of biopsy is the gold standard for differentiation between reversible steatosis and progressive steatohepatitis. There are numerous publications on this topic with the aim of developing uniform standards for biopsy diagnosis or identifying reliable non-invasive or only slightly invasive alternatives to biopsy, particularly driven by the increasing prominence of alcoholic and nonalcoholic steatohepatitis.
The publications on predisposition to ASH or NASH, however, cannot be uniformly interpreted because of ethnic or physiological differences among the populations analysed.
It is therefore important to evaluate the situation in Germany, Austria, as well as Switzerland (and, where applicable, the rest of Europe) objectively and work towards reasonable diagnostic procedures that serve the needs of these patients.
The goal of this guideline is thus to delineate the current state of knowledge with regard to the pathohistological diagnosis of ASH and NASH and to provide expert assessment of the non-invasive alternatives.
Definitions and diagnostic criteria

Definitions
An alcoholic (AFL) and a non-alcoholic fatty liver (NAFL) are characterised by variable deposition of lipids (principally triglycerides) in the hepatocytes. Involvement of more than 5% of hepatocytes is termed "fatty degeneration"; if more than 50% are affected, the patient has a "fatty liver". A subsequent inflammatory reaction with ballooning of the hepatocytes results in ASH or NASH. ASH or NASH may lead to fibrosis or cirrhosis.
Light microscopically detectable deposition of lipid droplets in the cytoplasm of hepatocytes is termed steatosis. Microvesicular and macrovesicular steatosis can be distinguished; mixed forms occur [4] .
The accumulation of fat in the liver essentially results from four pathogenetic processes: (1) increased uptake of free fatty acids (from food or body fat) via the portal vein; (2) increased synthesis of free fatty acids in the liver (from glucose or acetate); (3) decreased β-oxidation of free fatty acids (above all in the mitochondria); (4) decreased synthesis or secretion of lipoproteins (very low density lipoproteins, VLDL), the principal route for elimination of lipids from the liver [4] .
In the past, alcohol abuse-leading to AFL-was usually suspected as the cause of steatosis. Today, however, one frequently observes steatosis in (abdominal, visceral) adiposity, diabetes mellitus type II, and hyperlipidaemia-components of the so-called metabolic syndrome. Moreover, other factors such as medications, toxins or (rarely) congenital metabolic disorders (e.g., a-beta-lipoproteinaemia/hypobetalipoproteinaemia) or hormonal imbalances, as in polycystic ovary syndrome, may cause steatosis-NAFL. In some cases, the cause of steatosis remains unresolved [5] [6] [7] .
The morphological spectrum of the non-alcoholic fatty liver diseases (NAFLD) stretches-like that of alcoholic fatty liver disease-from simple steatosis over steatohepatitis to liver fibrosis and cirrhosis, and thus ultimately to hepatocellular carcinoma. Pure steatosis, unaccompanied by inflammation or fibrosis, is in principle reversible and generally displays an indolent, non-progressive course. Steatohepatitis is-from the hepatological viewpoint-the progressive lesion in this spectrum.
The diagnosis of NAFLD thus emerges from a combination of clinical (exclusion of significant alcohol consumption) and histopathological (demonstration of steatosis or steatohepatitis) findings. What constitutes immoderate (significant) alcohol consumption is controversial. Nowadays, an upper limit of 20 g of alcohol per day is accepted, in men up to 40 g/day [8, 9] . NAFLD is thought to be the most frequent liver disease in the western industrial nations and thus the commonest cause of elevated transaminases.
The prevalence of NAFL in the western industrial nations is assumed to be 20-30%, that of NASH, 2-3% [6, 10, 11] . There is a direct relationship with body weight; in obesity (BMI >30) the prevalence of sonographically detectable steatosis is 76-89%, compared with 46-50% in alcoholics [12] . NAFLD is increasingly being diagnosed in childhood, again predominantly in association with obesity, but occasionally with suprasellar tumours [13] .
The natural course of NAFLD in the individual case cannot be predicted. Only a small proportion of those affected show progression of their liver disease. The assumption is that simple steatosis will progress to NASH in around 10-20% of patients, and that of these, less than 5% will develop cirrhosis [11, 14, 15] . Nevertheless, NAFL and NASH are currently believed to be the most important cause of so-called cryptogenic cirrhosis of the liver [7, 16] .
The pathogenesis of NASH remains unclear, however, with many aspects unresolved. In Day and James's "twohit" hypothesis, simple steatosis, with an accumulation of free fatty acids and triglycerides in the liver, represents the first hit, rendering the organ more vulnerable to a second hit that leads to steatohepatitis and ultimately, in the event of persisting or recurring damage, to fibrosis and cirrhosis [17, 18] . A central part is played by insulin resistance, which can be demonstrated in virtually all patients [19] . Elevated peripheral lipolysis and decreased glucose uptake by the musculature form the basis for increased uptake of free fatty acids from the bloodstream and thus a rise in hepatic triglyceride synthesis and simultaneous inhibition of triglyceride secretion in the form of VLDL as a result of decreased apoprotein synthesis. The increase in the hepatic pool of free fatty acids leads to a rise mitochondrial and peroxisomal β-oxidation with formation of free oxygen radicals (reactive oxygen species) and development of oxidative stress and increased lipid peroxidation. Facilitated by the action of proinflammatory cytokines (via activation of NFκB, release of TNF-α), steatohepatitis develops. Via Kupffer cell activation, liver fibrosis or cirrhosis arises [7, 9, 10, 14, 15, [20] [21] [22] .
The possible direct or indirect (increased insulin resistance) role of the adipocyte hormones (leptin and adiponectin) in the pathogenesis of NASH remains largely unclear, as does the recently discussed influence of bacterial overgrowth in the small intestine with endogenous production of ethanol and possible direct cytokine activation [6, 21, 23] .
Diagnostic criteria
In clinical practice, it is impossible to differentiate reliably between simple steatosis and steatohepatitis solely on the basis of non-invasive (e.g., laboratory chemical) diagnostic tests. The diagnosis "steatosis" should be assigned when more than 5% of the hepatocytes display fat deposits. Steatohepatitis is present when steatosis is accompanied by mixed-cell inflammatory infiltrates in the hepatic lobes and damage (ballooning) of the hepatocytes.
Clinically, most patients with NAFLD exhibit no liver symptoms. The disease is often suspected merely on grounds of (mildly) raised transaminase levels and/or gamma-glutamyltranspeptidase. An ASAT to ALAT ratio of >1 points to an alcoholic aetiology. Patients with NASH often suffer from illnesses that go hand in hand with insulin resistance. However, the presence of a metabolic syndrome does not exclude alcoholic hepatopathy [24] . In clinical practice, there is so far no means of differentiating reliably between simple steatosis and steatohepatitis solely on the basis of non-invasive (e.g., laboratory chemical) diagnostic tests, i.e., without liver biopsy [7, 12, 25] . Moreover, histological demonstration of long-standing liver cell damage is believed to be the best available marker for evaluation of disease progression [26] . The question of whether transaminase levels correlate with the histological findings, particularly with necroinflammatory activity and the degree of fibrosis, has still not been answered definitively [27] . It was reported that determination of the hepatic apoptotic activity in serum (activated caspase 3, keratin-18 fragment analysis) may have clinical value as a non-invasive diagnostic criterion for NASH [28] . Furthermore, there have been isolated reports of non-invasive scoring systems for fibrosis, but their potential (diagnostic or prognostic) role in routine clinical practice remains unclear [7, 29] .
The morphological sign of non-alcoholic steatosis is a predominantly macrovesicular accumulation of lipids (mainly triglycerides) in the cytoplasm of hepatocytes, usually beginning at a perivenular site in the centre of a lobe. The lower limit has been set at fatty degeneration of 5% of the surface of the liver parenchyma [9, 30] , but this does not seem to be adequately justified [10, 31] . Mild steatosis affects <33% of the parenchymal surface, moderate steatosis involves 33-66%, and severe steatosis covers >66% [4, 8, [31] [32] [33] [34] [35] [36] [37] .
In NASH, the variable degree of steatosis is accompanied by (usually only slight) mixed-cell (neutrophilic, granulocytic, and lymphocytic) inflammatory infiltrate in the hepatic lobes. A further morphological criterion is the demonstration of liver cell damage in the form of swelling (ballooning), usually in the vicinity of fat-laden hepatocytes and thus also typically in the centre of a lobe. Other typical, albeit not diagnostically decisive, parameters are lipogranulomas and the demonstration of periportal glycogen containing nuclei. Mallory-Denk bodies (MDB)-usually small, poorly developed cytoplasmic inclusions-can be demonstrated in the swollen cells. The fibrosis also begins in the centre of the affected lobe, in perivenular and perisinusoidal locations; pericellular fibrosis (of the "chicken wire" type) is sometimes found. As the disease progresses, there is portal fibrosis with formation of bridging (portoportal and portocentral) septa. No single one of these parameters is diagnostic per se for NASH; even the combination of steatosis and (slight) lobular hepatitis should not be used as a so-called minimal criterion without the simultaneous demonstration of liver cell damage in the form of swelling (ballooning) [4, 8, 9, [31] [32] [33] [34] [35] [36] .
On prognostic grounds, the Cleveland group suggested classification of NAFLD into the following types: type 1, simple steatosis; type 2, steatosis and inflammation; type 3, steatosis and cell swelling (ballooning); type 4, steatosis, cell swelling (ballooning), and MDB or fibrosis. Progression to cirrhosis is found predominantly in types 3 and 4, both of which correspond to the typical histopathological picture of NASH [8, 9, 31-36, 38, 39] . For the morphological manifestations of paediatric NASH, see "Special form: paediatric fatty liver disease".
Finally, it should be pointed out that the structural diagnostic criteria for NAFLD may be unevenly distributed in the liver, so that histological diagnosis on the basis of biopsy samples may be associated with no inconsiderable sampling error [40] . This affects not only the diagnostic differentiation between steatosis and steatohepatitis but also estimation of the extent of fibrosis (staging); see also "Harvesting and processing of biopsy material/histomorphological evaluation/scoring system".
Indications for biopsy
Liver biopsy is the gold standard for confirmation of the diagnosis and for determination of the inflammatory activity and possible presence of fibrosis in fatty liver disease. In deciding whether biopsy is indicated, one should weigh the potential information gain and its consequences against the resources invested and the complication rate, i.e. consider the clinical context. No blanket recommendation for liver biopsy in either suspected or confirmed fatty liver disease can currently be given.
The indication for biopsy in assumed fatty liver disease depends on the clinical context. Decisive is the likelihood that the biopsy findings will have consequences for the patient's behaviour or for therapy. These possible consequences include: Liver biopsy is the current "gold standard" for analysis of these issues and cannot be replaced by any non-invasive procedure [35, [43] [44] [45] [46] [47] . It is advisable to discuss the implications of liver biopsy with the patient during the course of diagnostic clarification of possible or probable fatty liver disease. While a pronounced case of fatty liver can be diagnosed with some certainty from the findings of clinical examination and imaging procedures, particularly the extent of the fatty degeneration and the presence or absence of the many possible accompanying liver diseases cannot be determined with any certainty by non-invasive means. There are no serological tests for diagnosis or quantification of fatty degeneration of the liver parenchyma.
Comparative investigations have shown that elevation of serum transaminase concentrations can point to impairment of the hepatic parenchyma, but an absence of serum transaminase elevation in fatty liver disease does not exclude inflammatory activity in liver tissue [42] . While in principle, fatty liver disease is thought to be swiftly reversible and unlikely to progress, steatohepatitis entails a significant risk of progression to severe fibrosis or cirrhosis, so that the determination of inflammatory activity has considerable prognostic relevance [39, 41, [46] [47] [48] .
Numerous non-invasive procedures for diagnosis of liver fibrosis have been and are being developed. Serological tests are based on algorithms, some of which are independent of fibrosis while others integrate parameters associated with hepatic fibrogenesis [49] . Currently, these tests can support the diagnosis of advanced liver fibrosis, but alone, particularly in the presence of only slight to moderate changes, they can neither confirm nor exclude fibrosis with sufficient certainty; therefore, they are unsuitable for staging. Elastography is a method for determining the stiffness of the liver, which correlates with extent of fibrosis, at least during follow-up. Particularly the presence or absence of severe fibrosis/cirrhosis can be assessed with high accuracy [50] . The advantages of this method are its repeatability, its low inter-and intra-observer variability and its lack of side effects; its disadvantages are inadequate detection of slight and moderate fibrosis, lack of grading ability, significant interference by other liver changes (fatty degeneration, inflammatory activity, cholestasis, congestion) and by extrahepatic factors (morbid obesity, ascites) [51] . For these reasons the diagnostic potential of elastography in fatty liver disease has been evaluated in only a few studies to date, so the method has not yet been adequately validated. In particular, its role in the monitoring of the course of fatty liver disease should be further investigated. None of the tests mentioned above is suitable for assessment of destruction of hepatic architecture. Other procedures, e.g. magnetic resonance elastography for measurement of fibrosis [52] , are currently inadequately validated or not validated at all, and therefore cannot be recommended.
Although liver biopsy is superior to all other investigations with regard to the number of relevant parameters assessed and predictive power, it cannot always be recommended as diagnostic method in possible or sufficiently confirmed fatty liver disease. Several factors affect the decision whether or not to perform biopsy: & Because biopsy is an invasive technique, the information it can be expected to yield must be balanced against the resources invested and the-albeit low-complication rate. Harvesting and processing of biopsy material/ histomorphological evaluation/scoring system
Harvesting and processing of the biopsy cylinder should observe the standard recommendations for liver biopsy. Differentiation between ASH and NASH is generally not possible on histological criteria alone. Nevertheless, information may be yielded that may make differential diagnosis easier. Fatty degeneration, inflammatory changes and signs of damage to hepatocytes can be semiquantitatively pooled to yield the Brunt score or NAS (NAFLD activity score), offering a basis to decide whether steatohepatitis is present or not. The staging should also be evaluated according to the degree of fibrosis. Numerical scores alone should not replace histological diagnosis. Harvesting and processing of the biopsy sample observe the standard recommendations for liver biopsy. The cylinder should contain representative tissues, be about 25 mm long and/or contain 15 portal fields [56] . Fixation and processing are routine (4% neutral buffered formalin, embedding in paraffin with the usual dehydration and preparation of routine stains such as haematoxylin and eosin, Berlin blue for demonstration of iron, PAS-diastase stain and reticulin and connective tissue staining). Sirius red staining is recommended for morphometric assessment. Immunohistological staining is not routinely required. An immunohistochemical reaction with antibodies to keratin 7 or 19 can be carried out to facilitate demonstration of gall duct lesions. Sensitive depiction of any MDB that may be present can be achieved with ubiquitin antibodies. With regard to ballooning of hepatocytes, which is included in the scoring system, demonstration of the intermediate filament cytoskeleton with antibodies against keratin 8 or 18 may be helpful, as this cytoskeletal system is reduced in cell ballooning [57] . The staging of fibrosis is shown in Table 1 .
The following histological criteria should be considered when interpreting and diagnosing non-alcoholic steatohepatitis: micro-or macrovesicular fatty degeneration, fibrosis, lobular inflammation-typically comprising polymorphonuclear granulocytes, lymphocytes and activated Kupffer cellslipogranulomas, hepatocyte ballooning, acidophilic bodies, ceroid-containing macrophages and megamitochondria. Additional changes are MDB and glycogen-contaning nuclei.
Fatty degeneration, inflammatory changes and signs of damage to hepatocytes are often semiquantitatively pooled to yield the so-called Brunt score [58] ( Table 2) .
The NAS (NAFLD activity score; Table 3 ) is a refinement of the Brunt score, derived by separate semiquantification of each of the three components-steatosis, hepatocyte ballooning and lobular inflammation-and addition to form a total score.
Evaluation and semiquantitative analysis for grading [58] : This scoring system is readily reproducible and can provide the basis for deciding whether steatohepatitis should be diagnosed or not: 0-2, definitely no steatohepatitis; 3-4, questionable; 5 or more, definite steatohepatitis. The scoring can also be applied to paediatric cases [59, 60] .
The staging according to grade of fibrosis (Table 1 , after Kleiner et al. [30] ) should also be evaluated:
Stage 1 is divided into 1a with slight central fibrosis and 1b with dense perisinusoidal fibrosis accompanied by central vein sclerosis and adjacent perisinusoidal fibrous extension. Stage 1c is used only for portal fibrosis, which may certainly occur at an early stage. Stage 2 is portal and central fibrosis. In analogy with the staging of chronic hepatitis, stage 3 is bridging fibrosis and stage 4 corresponds to cirrhosis. The presence of MDB should also be recorded [61] .
The proposed scoring systems have not yet been generally accepted. Numerical scores alone should not replace histological diagnosis (Figs. 1, 2, 3, 4 , 5, 6, 7 and 8).
Diagnosis and differential diagnosis
The criteria for differentiation of NASH or ASH from hepatitis C virus infection are firstly the characteristic portal inflammatory infiltration pattern of HCV infection, and secondly the lack of typical hepatocyte ballooning and the intra-acinar granulocytic inflammation.
Differential diagnoses
It is important to differentiate between ASH and NASH and also to differentiate both of them from viral hepatitides and chemotoxicity-related steatohepatitides. The histopathological peculiarities of fatty liver diseases in the paediatric age group must also be borne in mind.
The criteria used for the morphological definition of steatohepatitis are fatty degeneration of liver cells (steatosis), predominant in zone 3, lobular and/or portal fielddominant inflammatory reaction (inflammation), direct liver cell damage in the form of ballooned hepatocytes, possibly MDB, fibrosis and possibly accumulation of iron. The numbers in parentheses give the NAS for each histological criterion -Steatosis Fatty degeneration of liver cells is documented in virtually all existing studies on ASH and NASH [4] . Macrovesicular steatosis results from the discrepancy between synthesis of lipids and their export from the hepatocytes. Microvesicular steatosis, a possible precursor of macrovesicular steatosis, is thought to be a consequence of severe hepatocytic damage as a result of defective β-oxidation of fatty acids. The toxic effects of some medicinal drugs can also lead to microvesicular steatosis. In the course of ASH or NASH, there may be complete loss of fat; thus, for example, cryptogenic cirrhosis with only slight fatty degeneration of liver cells is not infrequently ascribable to NASH [16, 62] . -Lobular and/or portal inflammation and hepatocyte ballooning ASH and NASH are characterised by a lobular inflammatory cell infiltrate with a variable number of leucocytes. Not infrequently, the inflammatory cells are found to enclose ballooned hepatocytes. So-called lipogranulomas, i.e. inflammatory cells (including Kupffer cells and eosinophilic granulocytes) enclosing a fat-laden hepatocyte, may be seen but are not considered pathognomonic for NASH or ASH [16, 63] . The direct hepatocyte damage is shown by the aforementioned ballooning, which may progress to necrosis or apoptosis. Hepatocytes of zone 3 are affected most frequently [4, 9, 31, 37] . MDB do not contribute to differentiation between ASH and NASH.
-Fibrosis
The characteristic fibrosis pattern in ASH and NASH is pericellular fibrogenesis. Collagen is found in the Disse spaces. In both ASH and NASH, zone 3 is affected first, with periportal fibrosis not infrequently observed in the liver of patients with diabetes mellitus type 1 (NASH patients). It seems that portal field fibrosis tends to predominate in ASH. Taken alone, however, this pattern of fibrosis is not a criterion for differentiation between ASH and NASH.
Differential diagnosis of alcoholic and non-alcoholic steatohepatitis
In general, histological criteria alone do not permit confident differentiation between ASH and NASH [63] . Nevertheless, some findings may be helpful in differential diagnosis [33, 59] , although to date there is no published evidence:
-Fat Microvesicular steatosis and "foamy" degeneration of the liver seem to indicate incipient hepatic decompensation in patients with ASH and are less common in NASH.
Patients with NASH usually exhibit more advanced fatty degeneration of liver cells than those with ASH. The affected hepatocytes, concentrated at periportal sites, more frequently display intranuclear vacuoles. In addition to the nuclear vacuoles, patients with diabetes mellitus show fibrosis usually starting in zone 1, where MDB may also be found. Patients with NAFL who display pronounced weight increase or a jejunoileal bypass tend to exhibit portal inflammation with only slight portal fibrosis. Only in decompensated ASH may any appreciable cholestasis occur, usually intracanalicular and sometimes with a secondary phenomenon such as pancreatitis or haemolysis as a contributory cause.
-Inflammation
As a general rule, the inflammatory infiltrate in NASH is somewhat less pronounced than in ASH. MDB are more frequent and more distinctive in ASH than they are in NASH. So-called satellitosis, granulocytic demarcation of a hepatocyte with MDB, is more frequent in ASH than in NASH.
-Fibrosis Indicative, though not specific, for ASH are the socalled sclerosing hyaline necroses, usually in combination with obliterating vascular lesions. The latter are also considered to be responsible for the non-cirrhotic portal hypertension in patients with ASH. Sclerosing hyaline necroses are thought to represent a combination of liver cell necrosis and loss (predominantly in zone 3) and dense perivenular and perisinusoidal fibrosis to the point of venous obliteration (with or without MDB). Venous or perivenular fibrosis, phlebosclerosis and (less commonly) lymphocytic phlebitis occur more frequently in ASH than in NASH. Phlebosclerosis is a frequent sign of alcohol-associated cirrhosis of the liver. Cholestasis is found in around a third of all livers with ASH, less often in patients with NASH. Ductular proliferates are encountered more frequently in ASH than in NASH.
Criteria for differentiation of ASH and NASH can be seen in Table 4 .
Differential diagnosis of ASH, NASH/hepatitis/ drug-induced hepatitis Differentiation among ASH/NASH, hepatitis C virus infection and liver damage by toxic effects of medications ("drug-induced hepatitis") is possible. In patients exhibiting signs of more than one of these diseases, discussion embracing the clinical parameters is necessary to identify the essential contributory factors.
The characteristic portal inflammatory infiltration pattern of HCV infection permits differentiation from ASH or NASH [64] . Combined manifestations occasionally have to be discussed in the light of the clinical data. Chronic HCV infection can also lead to macrovesicular steatosis. In particular, patients infected with HCV genotype 3 usually show more advanced fatty degeneration. However, the hepatocyte ballooning and intralobular granulocytic inflammation typical of ASH and NASH are absent.
Drug-induced hepatitis is characterised by portal and particularly intra-acinar inflammation that consists principally of neutrophilic and eosinophilic granulocytes. Cholestasis is found, and in severe cases liver cell necrosis. Steatosis does not necessarily occur in drug-induced hepatitis (exceptions include tamoxifen and amiodarone), but is often found in patients who evince certain risk factors (high BMI, diabetes mellitus).
Selected drugs that may lead to steatosis are listed in Table 5 .
Special form: chemotherapy-associated steatohepatitis Persons at increased risk of developing fatty liver are in greater danger of developing chemotherapy-associated steatohepatitis (CASH). Close monitoring of liver function before hepatic resection is recommended in these patients. Possible causes of elevation of liver enzymes before initiation of chemotherapy include malignant involvement of the liver and other chronic hepatic diseases as well as fatty liver disease. Liver biopsy may be necessary for differential diagnosis.
Chemotherapy and liver damage
Severe liver changes have been observed following chemotherapy administered in the context of liver resection, particularly extirpation of colorectal metastases. These adverse effects of chemotherapy on the liver tissue around a tumour can lead to postoperative impairment of liver function. The described changes resemble the histological findings after conditioning chemotherapy and subsequent allogenic stem cell transplantation in the liver. The liver damage after chemotherapy depends decisively on the degree of previous liver impairment. Neoadjuvant chemotherapy may be followed not only by sinusoidal obstruction syndrome [65] (SOS), but also by slight steatosis, steatohepatitis or even combined steatohepatitis and SOS [66] . In principal, any of the cell populations in the liver can be affected by drug-induced damage. Cholangiocytes are considered to be relatively inert. Hepatocytes, followed by vascular endothelia, are the primary cell systems in which damage may also be visible on light microscopy. The changes may extend as far as fibrosis, accompanied by vascular wall damage and parenchymal bleeding.
-Fatty degeneration of liver cells Fatty degeneration after chemotherapy with 5-fluorouracil (5-FU) is generally considered to be reversible after discontinuation of the treatment. Particularly in the case of pre-existing fatty liver, however, the rate of complications after liver resection is higher. Chemotherapy-induced fatty It is known that, for example, 5-FU, taxanes or platinum-containing chemotherapeutics exert oxidative stress not only on tumour cells but also on nonneoplastic parenchymal and stromal cells [67] . This prompted the proposal to adopt the term "chemotherapyassociated steatohepatitis" (CASH) [68, 69] . The metabolic pathway of some drugs is known in detail. Thus, the topoisomerase-I inhibitor irinotecan (CPT11) is thought to trigger CASH even in a previously intact liver. The damage is assumed to be predominantly hepatocytic because of the glucuronidation of hepatocytes. Sublethal liver damage may be manifested by hepatocyte ballooning, microvesicular steatosis and finally inflammation with subsequent fibrosis. Like ballooning, hepatocellular cholestasis is considered to be a sign of direct cell damage. In the treatment of colorectal carcinoma irinotecan is almost always used in combination with 5-FU, so the hepatotoxic effects may be additive.
Vascular endothelial damage
The endothelial cells can also be damaged by oxidative stress. Histologically, the vessels are occluded by connective tissue [69] [70] [71] [72] , with coexisting inflammation, fibrosis and embolic occlusion of small and larger downstream vessels. Damage of these cells in the terminal hepatic venules and sublobular veins causes on the one hand activation of the coagulation cascade (thrombosis) and on the other, hyperfibrinolysis (bleeding). These disseminated intravasal coagulations in the liver result in inflammation and subsequent fibrosis to the point of vascular occlusion. Macroscopically, the affected liver is rich in blood, spongy and livid ("blue liver"); its elasticity is diminished. Here too, the effects of various substances may be additive. Platinum-containing chemotherapeutics (particularly oxaliplatin) also possess high hepatotoxic potential (endothelial damage, sinusoidal lesions, SOS). Resected liver tissue from patients treated with a combination of 5-FU and oxaliplatin reveal, besides sinusoidal lesions with bleeding, vascular thrombosis and vascular fibrosis, signs of CASH, with hepatocytic necrosis, fatty degeneration of liver cells and cholestasis. These changes may be visible as early as 20 days after inception of therapy. The histological changes after administration of site-specific treatments, e.g. monoclonal antibodies against the EGF receptor or VEGF, have not yet been the subject of controlled studies.
-Classification system for staging
The precise relationship between fatty degeneration of liver cells and SOS has not yet been clearly defined. A further open question is the dose-effect relationship. Moreover, it remains unclear whether the histological changes are reversible. There seems to be no linear correlation between liver damage and elevated liver enzymes in peripheral blood. To date there is neither a clinical nor a histological classification or graduation system that would allow "staging" of the change, much less prediction of the outcome. Therefore, it can merely be recommended that liver function be closely monitored before liver resection in patients at risk of developing fatty liver (e.g. high BMI, metabolic syndrome, diabetes mellitus) [70, 73] . If the liver enzymes are elevated before initiation of chemotherapy and the cause is not tumour involvement, a full battery of laboratory tests may need to be accompanied by liver biopsy to establish the exact extent of fatty degeneration, ballooning or fibrosis. In particular, special attention should be paid to histological processing of the tissue surrounding the metastasis in specimens resected from patients who have undergone chemotherapy.
Special form: paediatric fatty liver disease Paediatric NASH exhibits histological differences from adult NASH; the sole clinical manifestation is usually a persistent slight elevation in transaminases. Before liver biopsy is considered, other chronic liver diseases should be ruled out and, when indicated, moderate weight reduction achieved. If still required, liver biopsy should then be performed for definitive confirmation of the diagnosis. The term non-alcoholic fatty liver (NAFL) is not restricted to adults but also used to describe the same condition in children and adolescents [74] . Accordingly, the term non-alcoholic steatohepatitis (NASH) is used in the paediatric age group for the more aggressive form of hepatocellular degeneration accompanied by fibrosis [75, 76] .
In about 80% of the affected children and adolescents, the NAFL is discovered incidentally in overweight or obese individuals. The remainder display normal weight but the majority are diabetics.
For assignment of the diagnosis of NAFLD in childhood or adolescence, fat has to make up at least 5-10% of the liver by weight. In analogy to the classification of fatty liver disease in adults, the steatosis is categorised as mild (less than a third of hepatocytes affected), moderate (up to two thirds of hepatocytes affected) or severe (more than two thirds of hepatocytes affected) [77] . Since some 4-8% of Germans in the paediatric age group, i.e. 500,000 to 1 million children and adolescents, are obese [77, 78] , around 400,000 are likely to have NAFLD. Among adults with NAFLD, 1-3% go on to develop cirrhosis of the liver. If this is true for the paediatric age group, then around 4,000 children and adolescents in Germany are at increased risk of early progressive liver fibrosis or cirrhosis. As in adult NAFLD, the only clinical manifestation is usually a persistent slight (one-to twofold) elevation in transaminases. The question of liver biopsy is controversial; nevertheless, there is consensus that, particularly in the event of repeated elevation of liver enzymes, chronic liver diseases such as hepatitis B and C, Wilson's disease and autoimmune hepatitides should first be ruled out. Weight reduction should be attempted. In patients who lose a moderate amount of weight over a period of 6 months but do not achieve normalisation of liver function, liver biopsy should be performed for definitive confirmation of the diagnosis and assessment of the prognosis. If at any time during this period evidence emerges of another disease or a competing or concurrent liver ailment (demonstration of autoantibodies, caeruloplasmin decrease), diagnosis should not be postponed until after weight reduction but ascertained immediately, with liver biopsy if necessary.
Differences between paediatric and adult NAFLD: To date there have been no studies on the prognosis of NAFLD. It also remains unclear what influence puberty and growth have on the time course of the disease. Adult NASH patients have a 25% risk of developing advanced liver fibrosis within 5 years and a 15% risk of cirrhosis in the same period [9] . The significance of ethnicity is hotly debated. Children of Hispanic and Asiatic origin are at greater risk. In contrast to the situation in adults with nonalcoholic liver disease, males are predominantly affected in the paediatric age group [65, 79] .
The first study on the histopathology of paediatric NAFLD and hepatitis found that they largely resemble the picture in adult disease, but display differing morphological aspects. With regard to inflammation and fibrosis, two subtypes can be distinguished [60] . In general, the livers of children and adolescents with NASH reveal less lobular and more portal inflammation, and the fibrosis tends to be more portal rather than perisinusoidal [75, 79, 80] . This distinctive histological feature could explain the early progression of the NAFLD score in children and adolescents compared with adults. Biopsy samples exhibit more marked fatty degeneration than in adult NASH. The characteristic ballooning of hepatocytes in adults is also absent, as is the pronounced lobular inflammation with perisinusoidal fibrosis. Only in 12% of cases is paediatric NAFLD histologically comparable to the adult disease [60, 81] . The differential diagnoses include Wilson's disease, other disorders of hepatic metabolism (including rare diseases) and chronic inflammatory bowel diseases, which may manifest as diarrhoea with weight loss. Differentiation from hepatitis is particularly important.
Perspective
At the moment, the question of genetic prevalence of NAFLD and NASH is under investigation and is obviously higher than estimated previously [82] . Recently, several genetic factors such as patatin-like phospholipase 3 or apolipoprotein C3 have been characterised in NAFLD [83, 84] .
Even genome-wide association studies of liver histology in patients with non-alcoholic fatty liver disease have been performed to estimate genetic susceptibility to NASH [85] . However, these findings have to be validated especially for the German/European population.
The consensus guideline is an S2-consensus guideline (AWMF S2k) and will be updated by the end of 2013, including all new data concerning genetic variability. When updated and adopted by all participating societies, genetic susceptibility will be included into the revised manuscript.
The question if NASH may be virus-associated, up to now, has been poorly addressed. The authors will include latest findings in the guideline update.
